TScan Therapeutics, Inc.
(NASDAQ : TCRX)

( )
TCRX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Commercial Services » Miscellaneous Commercial Services
symbolcompany%chnglast%shortavg$volume
ETSYEtsy, Inc. 2.65%237.457.5%$589.29m
EFXEquifax, Inc. 3.43%291.842.0%$203.45m
CHGGChegg, Inc. -4.28%28.1713.1%$166.00m
FLTFLEETCOR Technologies, Inc. 1.40%220.293.7%$147.50m
CPRTCopart, Inc. 3.36%150.624.4%$146.54m
CRLCharles River Laboratories International, Inc. 4.45%367.014.5%$135.72m
PSFEPaysafe Ltd. 2.11%3.640.0%$114.66m
CLVTClarivate Plc 3.85%24.850.0%$113.90m
ADGIAdagio Therapeutics, Inc. 19.06%38.730.0%$112.68m
FOURShift4 Payments, Inc. 4.03%57.000.0%$110.27m
TALTAL Education Group 5.49%4.710.7%$94.18m
PAGSPagSeguro Digital Ltd. 7.55%28.080.0%$92.40m
BKKTBakkt Holdings, Inc. 5.17%13.220.0%$85.03m
MRVIMaravai Lifesciences Holdings, Inc. 2.50%41.750.0%$71.14m
SYNHSyneos Health, Inc. 3.40%102.320.0%$70.40m

Company Profile

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.